Zanamivir

Zanamivir
Clinical data
Pronunciation	/zəˈnæmɪvɪər/
Trade names	Relenza
AHFS/Drugs.com	Monograph
License data	US DailyMed: Zanamivir;
Pregnancy; category	AU: B1; ;
Routes of; administration	Inhalation, intravenous
ATC code	J05AH01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	2% (oral)
Protein binding	<10%
Metabolism	Negligible
Elimination half-life	2.5–5.1 hours
Excretion	Kidney
Identifiers
	IUPAC name (2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid;
CAS Number	139110-80-8 ;
PubChem CID	60855;
DrugBank	DB00558 ;
ChemSpider	54842 ;
UNII	L6O3XI777I;
KEGG	D00902 ;
ChEBI	CHEBI:50663 ;
ChEMBL	ChEMBL222813 ;
PDB ligand	ZMR (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID0023749 ;
ECHA InfoCard	100.218.632
Chemical and physical data
Formula	C12H20N4O7
Molar mass	332.313 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)C=1O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](/N=C(\N)N)C=1;
	InChI InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1 ; Key:ARAIBEBZBOPLMB-UFGQHTETSA-N ;
	(verify)

Zanamivir is a medication used to treat and prevent influenza caused by influenza A and influenza B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B.^[3] Zanamivir was the first neuraminidase inhibitor commercially developed. It is marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.

^ "Relenza- zanamivir powder". DailyMed. 19 October 2021. Retrieved 30 September 2022.
^ "List of nationally authorised medicinal products" (PDF). European Medicines Agency.
^ "FDA Approves a Second Drug for the Prevention of Influenza A and B in Adults and Children FDA press release March 29, 2006". FDA. Archived from the original on 6 March 2010. Retrieved 16 December 2019.

[1] "Relenza- zanamivir powder". DailyMed. 19 October 2021. Retrieved 30 September 2022.

[2] "List of nationally authorised medicinal products" (PDF). European Medicines Agency.

[fda.gov-3] "FDA Approves a Second Drug for the Prevention of Influenza A and B in Adults and Children FDA press release March 29, 2006". FDA. Archived from the original on 6 March 2010. Retrieved 16 December 2019.

[1]

[2]

[3]